Director Paul Gendron purchases 5,000 shares on open market while stock trades well below 52-week highs; second open-market buy in 36 months.
Paul Gendron, a company director, is making a second open-market purchase of shares in InfuSystem, adding to a single prior buy from earlier in the 36-month window. The stock is currently trading well below its 52-week high, having declined significantly over the past month, creating a price environment where repeat insider buying typically occurs. InfuSystem remains profitable with growing revenue, trading at a moderate valuation—the type of fundamentals that might justify director confidence during a pullback. However, the timing of Gendron's prior open-market purchase revealed conflicting results: the stock fell slightly in the near term after that buy but recovered and gained over a longer three-month horizon. The current purchase at lower prices suggests he may be adding to a position he viewed favorably before, though the mixed outcomes from his previous trade mean this is not a pattern of flawless market timing.